共 26 条
- [1] Atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAFV600 mutation-positive melanoma with central nervous system (CNS) metastases (mets): Primary results from phase 2 Tricotel study.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Dummer, ReinhardQueirolo, PaolaGuijarro, Ana Maria AbajoHu, YouyouWang, DaoAzevedo, Sergio JobimRobert, CarolineAscierto, Paolo AntonioChiarion-Sileni, VannaPronzato, PaoloSpagnolo, FrancescoMujika, KarmeleLiszkay, GabriellaMerino, Luis De la CruzTawbi, Hussein A.
- [2] A phase II study evaluating atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAF-mutant melanoma and central nervous system (CNS) metastases (mets).JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Queirolo, Paolade la Cruz Merino, LuisAbajo Guijarro, Ana MariaTawbi, Hussein Abdul-HassanDummer, Reinhard
- [3] Evaluation of atezolizumab (A), cobimetinib (C), and vemurafenib (V) in previously untreated patients with BRAFV600 mutation-positive advanced melanoma: Primary results from the phase 3 IMspire150 trialCANCER RESEARCH, 2020, 80 (16)McArthur, A.Stroyakovskiy, DaniilGogas, HelenRobert, CarolineLewis, KarlProtsenko, SvetlanaPereira, RodrigoEigentler, ThomasRutkowski, PiotrDemidov, LevManikhas, Georgy MoiseevichYan, YibingHuang, K. C.Uyei, AnneMcNally, VirginaGutzmer, RalfAscierto, Paolo
- [4] Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot studyEUROPEAN JOURNAL OF CANCER, 2014, 50 (03) : 611 - 621Dummer, ReinhardGoldinger, Simone M.Turtschi, Christian P.Eggmann, Nina B.Michielin, OlivierMitchell, LadaVeronese, LuisaHilfiker, Paul ReneFelderer, LeaRinderknecht, Jeannine D.
- [5] Efficacy and safety of cobimetinib (C) combined with vemurafenib (V) in patients (pts) with BRAFV600 mutation-positive metastatic melanoma: analysis from the 4-year extended follow-up of the phase 3 coBRIM studyJOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Dreno, BrigitteAscierto, Paolo AntonioMcArthur, Grant A.Atkinson, VictoriaLiszkay, GabriellaDi Giacomo, Anna MariaMandala, MarioDemidov, Lev V.Stroyakovskiy, DaniilThomas, LucDe la Cruz-Merino, LuisDutriaux, CarolineGarbe, ClausRooney, Isabelle AnneHsu, Jessie J.Park, EricaRibas, AntoniLarkin, James M. G.
- [6] Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 studyANNALS OF ONCOLOGY, 2017, 28 (10) : 2581 - 2587Chapman, P. B.Robert, C.Larkin, J.Haanen, J. B.Ribas, A.Hogg, D.Hamid, O.Ascierto, P. A.Testori, A.Lorigan, P. C.Dummer, R.Sosman, J. A.Flaherty, K. T.Chang, I.Coleman, S.Caro, I.Hauschild, A.McArthur, G. A.
- [7] Vemurafenib in patients with BRAFV600 mutation-positive meta-static melanoma: final overall survival results of the BRIM-3 studyJOURNAL OF TRANSLATIONAL MEDICINE, 2016, 14Chapman, Paul B.Robert, CarolineLarkin, JamesHaanen, John B.Ribas, AntoniHogg, DavidHamid, OmidAscierto, Paolo AntonioTestori, AlessandroLorigan, PaulDummer, ReinhardSosman, Jeffrey A.Flaherty, Keith T.Yue, HuibinColeman, ShelleyCaro, IvorHauschild, AxelMcArthur, Grant A.
- [8] Time to development of central nervous system (CNS) metastases (mets) with atezolizumab (A) or placebo (P) combined with vemurafenib (V) plus cobimetinib (C): Updated results from the phase III IMspire150 studyANNALS OF ONCOLOGY, 2022, 33 (07) : S917 - S918Lewis, K.Robert, C.Munhoz, R. RamellaLiszkay, G.Merino, L. De la CruzOlah, J.Queirolo, P.Mackiewicz, J.Li, H.Zhu, Q.Hertig, C.Paranthaman, N.McKenna, E. F.Gutzmer, R.McArthur, G.Ascierto, P. A.
- [9] Time to central nervous system (CNS) metastases (mets) with atezolizumab (A) or placebo (P) combined with cobimetinib (C) plus vemurafenib (V) in the phase Ill IMspire150 study.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Ascierto, Paolo AntonioRobert, CarolineLewis, Karl D.Munhoz, RodrigoLiszkay, GabriellaMerino, Luis de la CruzOlah, JuditQueirolo, PaolaMackiewicz, JacekLi, HaochengZhu, QianMcNally, V.Mckenna, Edward FrancisGutzmer, RalfMcArthur, Grant A.
- [10] Overall survival (OS) with first-line atezolizumab (A) or placebo (P) in combination with vemurafenib (V) and cobimetinib (C) in BRAFV600 mutation-positive advanced melanoma: Second interim OS analysis of the phase 3 IMspire150 study.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)McArthur, Grant A.Gutzmer, RalfStroyakovskiy, DaniilGogas, HelenRobert, CarolineProtsenko, SvetlanaPereira, Rodrigo PerezEigentler, ThomasRutkowski, PiotrDemidov, Lev V.Zhukova, Natalia V.Schachter, JacobYan, YibingCaro, IvorHertig, ChristianXue, ClorisKusters, LiekeAscierto, Paolo AntonioLewis, Karl D.